middle.news
Optiscan’s Revenue Slumps 43% Amid Funding Crunch, Raises $17.75M for FDA Push
10:34am on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
Optiscan’s Revenue Slumps 43% Amid Funding Crunch, Raises $17.75M for FDA Push
10:34am on Wednesday 25th of February, 2026 AEDT
Key Points
43% decline in revenue to $339,227 for half-year ended December 2025
Net loss increased 43% to $3.4 million
Reduced sales of ViewnVivo device due to constrained US and China research funding
R&D expenses increased to accelerate clinical studies and FDA submissions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
OPTISCAN IMAGING (ASX:OIL)
OPEN ARTICLE